Form 4: Mereo BioPharma Executive Sells Shares to Cover Tax Obligations

Alexandra Hughes-Wilson, a Mereo BioPharma Group plc officer, sold American Depositary Shares (ADS) to cover tax withholding obligations related to vesting of restricted stock units and exercise of stock options.

Summary

• Alexandra Hughes-Wilson, Chief Patient Access and Commercial Planning at Mereo BioPharma Group plc, executed several transactions involving American Depositary Shares (ADS) in September 2024.
• On September 12, 2024, she sold 7,769 ADSs at a weighted average price of $4.4727 to cover tax withholding obligations related to the vesting of performance-based restricted stock units.
• Additionally, on the same day, she sold 40,029 ADSs at a weighted average price of $4.4727.
• On September 13, 2024, she sold 16,304 ADSs at a weighted average price of $4.221 and 84,008 ADSs at a weighted average price of $4.221.
• These sales were primarily to cover tax obligations related to the exercise of stock options.
• Following these transactions, Hughes-Wilson directly owns 50,475 ADSs.
• The total amount of securities beneficially owned on the reporting person's Form 4 filed on September 13, 2024 has been reduced by 44,296, which reflects ADSs withheld by the Issuer in connection with the net settlement of the stock option exercise on September 11, 2024 and inadvertently omitted from the September 13, 2024 filing.

Sentiment

Score: 5

Explanation: The document reflects routine transactions related to executive compensation and tax obligations, indicating a neutral sentiment.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often related to compensation and tax obligations. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a standard practice across the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen also see similar transactions by their executives regularly.
• The size and frequency of these sales are generally proportional to the executive's compensation package and the company's stock performance.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the purpose of the sales.
• Employees who also hold stock options or restricted stock units may be interested in the transaction details for their own financial planning.

Key Dates